Carlos César Bentim Pires
About Carlos César Bentim Pires
Carlos César Bentim Pires, who also goes by César Bentim, is based in São Paulo, Brazil. He has more than 25 years of experience in healthcare and pharmaceuticals, mainly in marketing, business strategy and innovation. Earlier in his career he held senior executive roles at Aché Laboratórios, Novo Nordisk and Wyeth. At Aché he directed business units with over 230 representatives and worked on marketing and sales strategy for over-the-counter (OTC/MIP) medicines.
He later became Director of Strategic Partner Relationships at IQVIA, the healthcare data analytics company. There he worked on partnerships with key stakeholders and on data-driven decision-making for healthcare organizations.
He founded ARTEGIST Healthcare Consulting in 2016 and directs it. The firm advises healthcare clients on marketing, branding and innovation. Its clients include ABIMIP, the Brazilian association of nonprescription medicine manufacturers, and SBMEE, the Brazilian Society of Exercise and Sports Medicine. He also teaches in the FIA Labfin Provar MBA program, run with SINDUSFARMA, and has taught pharmaceutical marketing at ESPM.
Crunchbase lists 2 investments by Carlos, both in one company, Riverdata. It dates them to July 2024 and May 2025. Crunchbase shows no lead investments, no exits and no companies founded. Round sizes and his check amounts are not public.
Riverdata is his only listed investment. It sells a platform that applies computer vision and AI in physical retail spaces, and Crunchbase places it in Rio de Janeiro. He is also an advisory board member there, starting July 2024, and works on bringing these technologies to pharmaceutical retail. His LinkedIn profile says he follows how applied AI affects business models and operations in healthcare, retail and distribution.
His public record is thin, so this is an inference from the one investment and his career. He appears to look at AI companies tied to healthcare, pharma and retail in Brazil, where he can also advise. Stage, check size and any stated investment criteria are not public. Founders in pharma retail, consumer health or healthcare data may find his experience most relevant.
- Riverdata: Rio de Janeiro company with a computer vision and AI platform for physical retail. He invested as an angel (Crunchbase dates: July 2024 and May 2025) and is an advisory board member.
Investing activity
Carlos César Bentim Pires has made 2 investments according to Crunchbase across 1 portfolio company.
Deals
Frequently asked questions about Carlos César Bentim Pires
Does Carlos César Bentim Pires invest in AI startups?
Yes, in at least one. Crunchbase lists his angel investment in Riverdata, a Brazilian computer vision and AI platform for physical retail. He also advises the company.
What check size does Carlos César Bentim Pires write?
It is not public. Crunchbase does not disclose his amounts, and we found no statement from him about check size.
What stage does Carlos César Bentim Pires invest in?
No stage is stated publicly. His one listed investment is an angel round.
What sectors is Carlos César Bentim Pires best placed to help with?
His background is in healthcare and pharmaceutical marketing, strategy and partnerships, including OTC medicines and healthcare data at IQVIA. He is most relevant to AI founders selling into pharma, pharmacy retail or consumer health in Brazil.
Where is Carlos César Bentim Pires based?
He is based in São Paulo, Brazil. ARTEGIST Healthcare Consulting is headquartered in São Paulo and, per a Guia da Farmácia author note, has a branch in Lisbon.
How many investments has Carlos César Bentim Pires made?
Crunchbase counts 2 investments in 1 portfolio company, with no lead rounds and no exits.
Is Carlos César Bentim Pires an angel investor?
Yes. Carlos César Bentim Pires invests personally as an angel. Crunchbase counts 2 investments.
How can founders reach Carlos César Bentim Pires?
Founders on Lounge can see Carlos César Bentim Pires's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with them under Warm Paths, and add Carlos César Bentim Pires to their Investor Pipeline to track the conversation.